Biosimilars

COVID-19

Cataract Surgery

Cataract

Cataract Therapeutics

Clinical Diagnosis

Cornea

Dry Eye Awareness

Dry Eye

Gene Therapy

Geographic Atrophy

IOL Advances

Imaging

Glaucoma Awareness

Glaucoma Insights

Therapeutic Glaucoma

Interventional Glaucoma

Ocular Allergy

Ocular Surface Disease

Optic Relief

Optometry

Pediatrics

Pharmacy

Indispensable

Practice Management

Presbyopia

Ptosis

Refractive Surgery

Refractive

Retina

Surgery

Technology

Therapeutics

Understanding Antibiotic Resistance

Workplace

News

All News

Contributors

Money Matters

Media

Expert Interviews

Medical World News

Podcasts

Case Based Roundtable Series

Case of the Quarter

EyeView

Grand Rounds

Insights

Rapid Readout

Viewpoints

What’s Your WhEYE?

Conferences

Conference Coverage

Conference Listing

Events

Publications

Digital Edition

Europe Ophthalmology Times

Modern Retina

Supplements and Featured Publications

Partners

Subscribe

Resources

Job Board

About

Advertise

Privacy

Editorial

Terms and Conditions

Contact Us

Do Not Sell My Personal Information

Ophthalmology Times - Ophthalmology news, articles, and events

Facebook

Instagram

LinkedIn

Spotlight

Clinical

Glaucoma

1rem

Sahar Bedrood, MD, PhD, glaucoma and cataract specialist at Acuity Eye Group (Pasadena, CA), clinical assistant professor at USC Roski Eye Institute, shares her clinical perspective on the evolution of interventional glaucoma, including the shift in standard treatment procedures and why taking an active approach to treating patients is key for success.

In this latest EyePod® episode, Sahar Bedrood, MD, PhD, shares her clinical perspective on the multi-faceted, dynamic evolution of interventional glaucoma. 

Exploring the evolution of interventional glaucoma



During AAO 2020, Thomas Samuelson, MD, speaks on the outcomes of a three-year trial analyzing the iStent inject trabecular micro-bypass + phaco versus phaco alone in patients with POAG.

Thomas Samuelson, MD, speaks on the outcomes of a three-year trial analyzing the iStent inject trabecular micro-bypass + phaco versus phaco alone in patients with POAG.

Comparing micro-bypass implant + phaco vs phaco in POAG

SpyGlass Pharma completed enrollment in a Phase 1/2 trial evaluating its drug delivery platform for glaucoma and ocular hypertension. Designed for implantation during cataract surgery, the platform delivers bimatoprost to lower intraocular pressure for up to 3 years.

SpyGlass Pharma completes enrollment in Phase I/II study of its long-term drug delivery platform for glaucoma and ocular hypertension

The weekly drug-eluting contact lens was created by the company’s proprietary 3D printing technology and met all primary endpoints with no serious adverse events reported in either cohort.

MediPrint Ophthalmics reveals positive results from phase 2b study of LL-BMT1 contact lens

The option gives Glaukos exclusive global license agreements on pre-agreed terms, including upfront and milestone payments plus royalties.

Nicox, Glaukos sign exclusive NCX 1728 research and global licensing option agreement

According to the company, its ViaLase Laser combines state-of-the-art femtosecond laser technology with micron-level image guidance to deliver the first femtosecond laser, image-guided, high-precision trabeculotomy (FLigHT), marking a shift in glaucoma care.

ViaLase receives CE mark for first femtosecond laser for treatment of glaucoma

According to Stuart, the agreement will grant Glaukos exclusive worldwide rights to develop and commercialize the company’s ST-113 drug candidate for neuroprotection in glaucoma.

Stuart Therapeutics announces licensing deal with Glaukos 

Videos

Glaukos Corporation's COO Chris Calcaterra gives an update on the company's latest  24-month phase 2b data for its iDose TR sustained-release travoprost implant, next steps for securing FDA approval, and his outlook for 2021. 

Glaukos COO shares product updates, 2021 pipeline 

Oluwatosin U. Smith, MD, Glaucoma Associates of Texas, provides an update on optimization and surgical modifications of newer glaucoma surgeries.


Optimizing and modifying newer glaucoma surgeries

Joseph F. Panarelli, MD, associate professor of ophthalmology, NYU Langone Medical Center, shares some clinical pearls for managing masquerade syndromes and determining when it is not glaucoma.

When is it not glaucoma: Masquerade syndromes

Donald L. Budenz, MD, MPH, shares the key takeaways from his Shaffer-Hetherington-Hoskins Lecture, focusing on glaucoma epidemiology, presented during the 2021 Glaucoma 360's 25th Annual Glaucoma Symposium CME. 

Studying glaucoma epidemiology at the center of the Earth 

Robert L. Stamper, MD, discusses the findings of a study analyzing the effects of corneal mechanics on IOP, presented during the virtual Glaucoma 360 meeting.

Analyzing effects of corneal biomechanics on IOP 

Read the article on Dr. William's presentation here

During the 2021 Glaucoma 360 meeting, Ruth D. Williams, MD, speaks on the highlights and key findings from the EAGLE study, which showed clear lens extraction surgery may be a better initial treatment for some glaucoma patients.

Treating PAC, PAC glaucoma with CLE

Tanner Ferguson, MD, an ophthalmology resident at the Cleveland Clinic's Cole Eye Institute, discusses findings from the study "Trabecular Micro-bypass Stent Implantation (iStent)" + Phacoemulsification in PXG: Six-Year Outcomes," during the virtual AAO 2020 meeting. 


Tanner Ferguson, MD, Cole Eye Institute, discusses findings from the study "Trabecular Micro-bypass Stent Implantation (iStent)" + Phacoemulsification in PXG: Six-Year Outcomes," during the virtual AAO 2020 meeting. 

Evaluating long-term safety of micro-bypass implant with phaco in PXG


During AAO 2020, Davinder Grover, MD, MPH, glaucoma specialist, Glaucoma Associates of Texas speaks on the highlights of his presentation regarding outcomes of a 12-year study comparing ab externo vs ab interno xen gel stents in tertiary glaucoma practice.


Davinder Grover, MD, MPH, speaks on the highlights of his presentation regarding outcomes of a 12-year study comparing ab externo vs ab interno xen gel stents in tertiary glaucoma practice. 

(AAO) Comparing outcomes of xen gel stents in glaucoma practice

harmaceutical representatives share what keeps them up at night within the ophthalmic and glaucoma space while attending the 2020 

Chris Adams, Diopter Corp (CEO); Daria Lemann-Blumenthal, BELKIN Laser Ltd (CEO); Victor Chan, MB, MS, director of U.S. Surgical Device Commercial Marketing (Santen, Inc); Ramin Valian, vice president of International Glaucoma, Reimbursement and Pipeline (Allergan).

Pharmaceutical representatives share what keeps them up at night within the ophthalmic space.

What keeps you up at night in ophthalmology: Part II

ICYMI: Ramin Valian, vice president of International Glaucoma, Reimbursement and Pipeline at Allergan, discusses the takeaways from a panel discussion on the progression of glaucoma from a therapeutics/diagnostics and big data sets standpoint during the 2020 Glaucoma 360 meeting in San Francisco, California.

ICYMI: Ramin Valian, vice president of International Glaucoma, Reimbursement and Pipeline at Allergan, discusses glaucoma from a therapeutics/diagnostics and big data sets standpoint during the 2020 Glaucoma 360 meeting.

Therapeutic Glaucoma

Latest News